Merck Total Assets 2006-2018 | MRK

Merck total assets from 2006 to 2018. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Merck total assets for the quarter ending December 31, 2018 were $82.637B, a 5.96% decline year-over-year.
  • Merck total assets for 2018 were $82.637B, a 5.96% decline from 2017.
  • Merck total assets for 2017 were $87.872B, a 7.87% decline from 2016.
  • Merck total assets for 2016 were $95.377B, a 6.2% decline from 2015.
Merck Annual Total Assets
(Millions of US $)
2018 $82,637
2017 $87,872
2016 $95,377
2015 $101,677
2014 $98,167
2013 $105,645
2012 $106,132
2011 $105,128
2010 $105,781
2009 $112,314
2008 $47,196
2007 $48,351
2006 $44,570
2005 $44,846
Merck Quarterly Total Assets
(Millions of US $)
Q4 2018 $82,637
Q3 2018 $85,130
Q2 2018 $85,040
Q1 2018 $86,041
Q4 2017 $87,872
Q3 2017 $91,676
Q2 2017 $92,804
Q1 2017 $96,561
Q4 2016 $95,377
Q3 2016 $98,335
Q2 2016 $96,475
Q1 2016 $98,755
Q4 2015 $101,677
Q3 2015 $101,232
Q2 2015 $102,582
Q1 2015 $108,345
Q4 2014 $98,167
Q3 2014 $101,808
Q2 2014 $97,860
Q1 2014 $108,460
Q4 2013 $105,645
Q3 2013 $106,419
Q2 2013 $106,876
Q1 2013 $106,200
Q4 2012 $106,132
Q3 2012 $106,301
Q2 2012 $105,525
Q1 2012 $105,509
Q4 2011 $105,128
Q3 2011 $106,534
Q2 2011 $106,195
Q1 2011 $105,865
Q4 2010 $105,781
Q3 2010 $107,840
Q2 2010 $106,171
Q1 2010 $111,594
Q4 2009 $112,314
Q3 2009 $48,739
Q2 2009 $49,407
Q1 2009 $46,543
Q4 2008 $47,196
Q3 2008 $48,546
Q2 2008 $47,458
Q1 2008 $47,041
Q4 2007 $48,351
Q3 2007 $45,701
Q2 2007 $44,183
Q1 2007 $42,993
Q4 2006 $44,570
Q3 2006 $43,719
Q2 2006 $43,479
Q1 2006 $43,418
Q4 2005 $44,846
Q3 2005 $43,831
Q2 2005 $43,006
Q1 2005 $43,117
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $223.649B $42.294B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $370.509B 16.88
Pfizer (PFE) United States $252.104B 14.12
Novartis AG (NVS) Switzerland $216.355B 18.40
Eli Lilly (LLY) United States $132.855B 23.08
Novo Nordisk (NVO) Denmark $127.479B 20.62
AbbVie (ABBV) United States $119.836B 10.27
Sanofi (SNY) France $113.942B 14.06
AstraZeneca (AZN) United Kingdom $108.788B 12.41
GlaxoSmithKline (GSK) United Kingdom $102.300B 13.43
Bristol-Myers Squibb (BMY) United States $79.871B 12.29